firing up my L2's
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Tanker COOL earnings amc
Gapper LEN earnings Tues bmo
Gapper KORS earnings pre
Note to APOL: shorting you to ZAY-ROW if Obama wins
APOL color: SAN FRANCISCO (MarketWatch) -- Apollo Group Inc. shares plunged as much as 17% in
early trades Wednesday after the for-profit education provider was hit by
downgrades from several equities analysts following a weak earnings report.
Apollo, citing declining enrollment numbers, announced late Tuesday its fiscal
fourth-quarter profit fell 60% from a year ago. It also trimmed its full-year
revenue outlook to $3.65 billion to $3.8 billion, less than the $4.07 billion
analysts were looking for. The weak results and outlook overshadowed steep cost
cuts Apollo is putting in place. Analysts at Credit Suisse, Deutsche Bank Markets
Research and BMO Capital Markets were among those who cut their targets on the
company. Apollo shares were last trading 17% lower at $22.81, a 52-week low. The
stock is down 46% from where it traded a year ago.
OSG color: Shares of Overseas Shipholding Group Inc. (OSG, $3.76, -$1.41, -27.27%) took
a big hit amid investor concern that it has maxed out it lending facilities and
could soon face a liquidity squeeze. Shares have been on the decline pretty
much since 2008 amid a rough shipping market. Debtwire, citing two hedge fund
analysts, said late last week that Goldman Sachs and UBS are shopping around
about $100 million in the tanker's revolver, looking to create a market for the
debt before OSG needs to refinance early next year.
Tanker BIOF just cuz it's bloated piglet after the r/s
GCI yeah missed on top line last q, prolly a good tanker lol
It should be updated with a downtrend line already
SPY chart updated, sorry haven't been around much
LOL...I been hooked since RIMM I guess...and I'm too busy right now to do my own research
Gapper VOXX just a guess on a big move either way
SPY getting hammered! chart 1 back
GMCR 2 negative notes on the street regarding increased competition
OTR Global and Dougherty both with concerning pieces on $GMCR, says $KFT will compete directly and losing shelf space
Wednesday's biggest gaining and declining stocks
By Greg Morcroft, MarketWatch
Last Update: 10/10/2012 08:59:19 AM
NEW YORK (MarketWatch) -- Here are some of Wednesday's biggest gaining and
declining stocks in premarket trade:
Gainers
AuRico Gold Inc. shares rose 11%. Canaccord Genuity upgraded the stock to buy
from hold after the Toronto-based company agreed to sell for $750 million its
Ocampo mine in Mexico and other properties to Minera Frisco SAB .
True Religion Apparel Inc. climbed 21% after the company said it was approached
by third parties about a possible deal and it formed a special committee to
evaluate its options, including a possible sale.
Decliners
CommonWealth REIT shares fell 8.4%. The firm is cutting its quarterly dividend in
half to 25 cents a share.
Cummins Inc. shares fell 5%. The company said late Tuesday it plans to lay off
between 1,000 and 1,500 workers worldwide by the end of 2012, as the Columbus,
Ind.-based company lowered its 2012 forecast for revenue and earnings before
interest and taxes.
Ferro Corp. shares fell 10% after the company late Tuesday lowered its profit
outlook for 2012.
Helen of Troy Corp. shares fell 5% after the consumer products company said it
expects fiscal 2013 earnings of $3.50 to $3.60 a share, below the Wall Street
estimate of $3.76 a share.
PAY thanks for the insight ico
PAY you'd think it was a solar stock from looking at that chart! crazy how these emerging market stocks get hit while overall market up so much
Market has Kass' blessing to go higher now:
@DougKass
Apples shares just breached the $630.50 support line from August 16 - I have covered my QQQ short. $AAPL $QQQ
EW, another guidance hit
Co issues downside guidance for Q3 (Sep), sees Q3 (Sep) revs of $448 mln vs. $476.56 mln Capital IQ Consensus Estimate. This represents a growth rate of approximately 9 percent, or 14 percent excluding the impact of foreign exchange. This compares to the Company's guidance of $465 million to $485 million provided during its second quarter earnings conference call on July 24, 2012. Transcatheter heart valve sales were below expectations for the third quarter, with global sales estimated at $124 million, including U.S. sales of $55 million. "In Europe, austerity measures tempered procedural volumes, resulting in underlying sales comparable to the same period a year ago. In the U.S., we are pleased with the overall progress of the launch, with training of commercial sites continuing as planned and procedural success rates remaining high. However, under the provisions of the National Coverage Decision, there was no reimbursement for inoperable patients without femoral access. A clinical protocol that would allow reimbursement for this sizable group of patients was expected earlier; it is now anticipated in the next several weeks. Additionally, due to the requirement that a full Heart Team be present for every procedure, summer vacations had a more pronounced effect.... Despite the third-quarter sales shortfall, we anticipate a strong rebound in the fourth quarter. The pending FDA approval to expand the indication to treat U.S. high-risk patients with SAPIEN, as well as the recent addition of our larger 29mm valve and a third delivery approach to our clinical trial, will make this therapy available to a considerably broader group of patients. Assuming this FDA approval happens early this quarter, for full-year 2012, we expect to achieve the low end of both our current global THV sales guidance of $550 million to $600 million, and our U.S. THV sales guidance of $240 million to $260 million. We remain enthusiastic about the potential of this transformative technology to improve the lives of many of the patients who suffer from severe aortic stenosis..."
EW, another guidance hit
Co issues downside guidance for Q3 (Sep), sees Q3 (Sep) revs of $448 mln vs. $476.56 mln Capital IQ Consensus Estimate. This represents a growth rate of approximately 9 percent, or 14 percent excluding the impact of foreign exchange. This compares to the Company's guidance of $465 million to $485 million provided during its second quarter earnings conference call on July 24, 2012. Transcatheter heart valve sales were below expectations for the third quarter, with global sales estimated at $124 million, including U.S. sales of $55 million. "In Europe, austerity measures tempered procedural volumes, resulting in underlying sales comparable to the same period a year ago. In the U.S., we are pleased with the overall progress of the launch, with training of commercial sites continuing as planned and procedural success rates remaining high. However, under the provisions of the National Coverage Decision, there was no reimbursement for inoperable patients without femoral access. A clinical protocol that would allow reimbursement for this sizable group of patients was expected earlier; it is now anticipated in the next several weeks. Additionally, due to the requirement that a full Heart Team be present for every procedure, summer vacations had a more pronounced effect.... Despite the third-quarter sales shortfall, we anticipate a strong rebound in the fourth quarter. The pending FDA approval to expand the indication to treat U.S. high-risk patients with SAPIEN, as well as the recent addition of our larger 29mm valve and a third delivery approach to our clinical trial, will make this therapy available to a considerably broader group of patients. Assuming this FDA approval happens early this quarter, for full-year 2012, we expect to achieve the low end of both our current global THV sales guidance of $550 million to $600 million, and our U.S. THV sales guidance of $240 million to $260 million. We remain enthusiastic about the potential of this transformative technology to improve the lives of many of the patients who suffer from severe aortic stenosis..."
BIDU...wow that is big! Are the chinese going back to using phonebooks?
Lebed
OCLR darn missed that one, these guidance downgrades are nice shorts
Tanker PTNT lebed pump
VRNG had the dilution news the other day too, maybe a good bop
wrong chart dummy! :-p
GDOT down 21% on this:
8:04 EDT - American Express (AXP) has in fact decided to enter the pre-paid
card realm in full force, going forward to launch Bluebird at Wal-Mart (WMT)
stores. AXP has been testing it for nearly a year, and March's disclosure of
that caused shares of prepaid-card purveyor Green Dot (GDOT)--which has relied
heavily on WMT customers for its own business--to slide, a decline that's
worsened since July competition-fueled sharp outlook cut from GDOT. Its stock
is down 59% this year and has dropped another 10% premarket to $11.35.
(kevin.kingsbury@dowjones.com)
AAPL lol my goodness how crazy is this...talk about jinxing a stock these ppl are doing their best!
CSTR forgive my laziness here, but are they trying to get these coffee kiosks all over the place like the DVD ones?
nice pick ico! biotechs are crazy
Tanker STZ, earnings, chart overdone? just a quick guess..